Track record Michael Thiess:
Investment advice – Elaboration and successful implementation of investment strategies
- Screening of various Venture Capital Life Science funds
- Investment recommendations for Venture Capital Life Science funds
Business Development – Partnering and portfolio optimization
- Licensing partner search for an immunomodulatory molecule in phase I/II
- Portfolio optimization for an oncology company
- Portfolio optimization for an intensive care company
Venture Support – Company strategy and financing
- Optimization of the business plan and VC-financing for a medtech company
M&A-Support – Identification and addressing of target candidates
- Optimization of the product and customer portfolio of an IT company in the healthcare sector
- Market entry strategy for Europe for a middle-sized Chinese pharmaceutical company
Track record Dr. Michael Thiel:
Investment advice – Elaboration and implementation of investment strategies
- Screening of various Venture Capital Life Science funds
- Investment recommendations for Venture Capital Life Science funds
Business Development – Partnering and portfolio optimization
- Market entry of the blockbuster product Olmetec (Olmesartan/hypertonia) in Europe
- Life cycle management for Olmesartan (introduction of fix combinations, new indications)
- Early entry strategy for Pravastatin (CSE inhibitor ) in Europe
- Partner search (Co-Development) for new immunomodulator for phase I/II
- Portfolio optimization for an intensive care company
M&A-Support – Identification and addressing of target candidates
- Licensing/acquisition deals in the magnitude of more than 1 bill. $, e.g. Olmesartan partnering in Europe with Menarini, Pfizer